Form 20-F ☑
|
Form 40-F ☐
|
Yes ☐
|
No ☑
|
EXFO INC.
|
|
By: /s/ Philippe Morin
Name: Philippe Morin
Title: Chief Executive Officer
|
|
§
|
Sales increase 23.4% to US$72.2 million, including US$8.6 million from Astellia
|
§
|
Bookings improve 14.8% to US$73.1 million, including US$7.6 million from Astellia
|
§
|
Cash flows from operations total US$4.7 million
|
Three months
ended
May 31, 2018
|
Three months
ended
May 31, 2017
|
Nine months
ended
May 31, 2018
|
Nine months
ended
May 31, 2017
|
|||||||||||||
Physical-layer sales
|
$
|
43,760
|
$
|
41,007
|
$
|
129,734
|
$
|
121,061
|
||||||||
Protocol-layer sales
|
28,278
|
17,678
|
69,799
|
59,784
|
||||||||||||
Foreign exchange gains (losses) on forward exchange contracts
|
179
|
(180
|
)
|
797
|
(525
|
)
|
||||||||||
Total sales
|
$
|
72,217
|
$
|
58,505
|
$
|
200,330
|
$
|
180,320
|
||||||||
Physical-layer bookings
|
$
|
44,796
|
$
|
47,157
|
$
|
134,579
|
$
|
125,278
|
||||||||
Protocol-layer bookings
|
28,115
|
16,691
|
69,179
|
60,692
|
||||||||||||
Foreign exchange gains (losses) on forward exchange contracts
|
179
|
(180
|
)
|
797
|
(525
|
)
|
||||||||||
Total bookings
|
$
|
73,090
|
$
|
63,668
|
$
|
204,555
|
$
|
185,445
|
||||||||
Book-to-bill ratio (bookings/sales)
|
1.01
|
1.09
|
1.02
|
1.03
|
||||||||||||
Gross margin before depreciation and
amortization*
|
$
|
43,254
|
$
|
33,950
|
$
|
122,752
|
$
|
109,963
|
||||||||
59.9
|
%
|
58.0
|
%
|
61.3
|
%
|
61.0
|
%
|
|||||||||
Other selected information:
|
||||||||||||||||
IFRS net earnings (loss) attributable to the parent interest
|
$
|
(5,970
|
)
|
$
|
(4,304
|
)
|
$
|
(7,951
|
)
|
$
|
7
|
|||||
Amortization of intangible assets
|
$
|
4,210
|
$
|
1,046
|
$
|
8,385
|
$
|
2,241
|
||||||||
Stock-based compensation costs
|
$
|
440
|
$
|
372
|
$
|
1,280
|
$
|
983
|
||||||||
Restructuring charges
|
$
|
–
|
$
|
3,813
|
$
|
–
|
$
|
3,813
|
||||||||
Change in fair value of cash contingent consideration
|
$
|
–
|
$
|
–
|
$
|
(716
|
)
|
$
|
–
|
|||||||
Acquisition-related deferred revenue fair value adjustment
|
$
|
913
|
$
|
–
|
$
|
1,222
|
$
|
–
|
||||||||
Income tax expense for US tax reform
|
$
|
–
|
$
|
–
|
$
|
1,528
|
$
|
–
|
||||||||
Net income tax effect of the above items
|
$
|
(138
|
)
|
$
|
(357
|
)
|
$
|
(704
|
)
|
$
|
(583
|
)
|
||||
Foreign exchange gain
|
$
|
(160
|
)
|
$
|
(1,725
|
)
|
$
|
(1,386
|
)
|
$
|
(1,965
|
)
|
||||
Adjusted EBITDA*
|
$
|
2,549
|
$
|
2,300
|
$
|
11,100
|
$
|
13,496
|
·
|
Sales. IFRS sales increased 23.4% year-over-year to US$72.2 million due to a strong performance from the Protocol-layer product line, revenue contributions from the Astellia and Yenista Optics acquisitions, and the positive impact of the decrease in the average value of the US dollar versus other currencies. Physical-layer sales accounted for 61% of revenue in the third quarter of 2018, while Protocol-layer sales totaled 39%. Revenue breakdown among the three main selling regions amounted to 49% in the Americas, 35% in Europe, Middle East and Africa (EMEA) and 16% in Asia-Pacific. EXFO's top customer accounted for 5.7% of sales, while the top three represented 15.2%.
|
·
|
Profitability. IFRS net loss totaled US$6.0 million in the third quarter of 2018, while adjusted EBITDA amounted to US$2.5 million. The company also generated US$4.7 million in cash flows from operations in the third quarter.
|
·
|
Innovation. EXFO held its inaugural Innovation Summit in early May with a focus on artificial intelligence and machine learning. More than 100 team members from four continents participated in the three-day event which featured a hackathon and presentations from distinguished speakers. EXFO launched two products during the third quarter, including an automated network troubleshooting solution that links performance measurements to network topology in order to deliver service degradation diagnosis in record time. The company also released the CTP10 Component Test Platform, with related modules, for measuring insertion loss and return loss on a wide range of passive optical components.
|
Three months
ended
May 31, 2018
|
Three months
ended
May 31, 2017
|
Nine months
ended
May 31, 2018
|
Nine months
ended
May 31, 2017
|
|||||||||||||
IFRS sales
|
$
|
72,217
|
$
|
58,505
|
$
|
200,330
|
$
|
180,320
|
||||||||
Acquisition-related deferred revenue fair value adjustment
|
913
|
–
|
1,222
|
–
|
||||||||||||
Non-IFRS sales
|
$
|
73,130
|
$
|
58,505
|
$
|
201,552
|
$
|
180,320
|
Three months
ended
May 31, 2018
|
Three months
ended
May 31, 2017
|
Nine months
ended
May 31, 2018
|
Nine months
ended
May 31, 2017
|
|||||||||||||
IFRS net earnings (loss) attributable to the parent interest for the period
|
$
|
(5,970
|
)
|
$
|
(4,304
|
)
|
$
|
(7,951
|
)
|
$
|
7
|
|||||
Add (deduct):
|
||||||||||||||||
Depreciation of property, plant and equipment
|
1,555
|
1,029
|
3,972
|
2,894
|
||||||||||||
Amortization of intangible assets
|
4,210
|
1,046
|
8,385
|
2,241
|
||||||||||||
Interest and other expense
|
198
|
57
|
870
|
28
|
||||||||||||
Income taxes
|
1,363
|
2,012
|
5,424
|
5,495
|
||||||||||||
Stock-based compensation costs
|
440
|
372
|
1,280
|
983
|
||||||||||||
Restructuring charges
|
–
|
3,813
|
–
|
3,813
|
||||||||||||
Change in fair value of cash contingent consideration
|
–
|
–
|
(716
|
)
|
–
|
|||||||||||
Acquisition-related deferred revenue fair value adjustment
|
913
|
–
|
1,222
|
–
|
||||||||||||
Share in net loss of an associate
|
–
|
–
|
2,080
|
–
|
||||||||||||
Gain on deemed disposal of the investment in an associate
|
–
|
–
|
(2,080
|
)
|
–
|
|||||||||||
Foreign exchange gain
|
(160
|
)
|
(1,725
|
)
|
(1,386
|
)
|
(1,965
|
)
|
||||||||
Adjusted EBITDA for the period (1)(2)
|
$
|
2,549
|
$
|
2,300
|
$
|
11,100
|
$
|
13,496
|
||||||||
Adjusted EBITDA as a percentage of sales
|
3.5
|
%
|
3.9
|
%
|
5.5
|
%
|
7.5
|
%
|
(1)
|
Astellia negatively impacted adjusted EBITDA by $2.2 million and $3.4 million respectively for the three and nine months ended May 31, 2018 (nil in 2017).
|
(2)
|
Includes acquisition-related costs of $2.1 million for the nine months ended May 31, 2018 and $0.1 million and $0.8 million respectively for the three and nine months ended May 31, 2017.
|
As at
May 31,
2018
|
As at
August 31,
2017
|
|||||||
Assets
|
||||||||
Current assets
|
||||||||
Cash
|
$
|
18,489
|
$
|
38,435
|
||||
Short-term investments
|
990
|
775
|
||||||
Accounts receivable
|
||||||||
Trade
|
46,756
|
41,130
|
||||||
Other
|
4,997
|
3,907
|
||||||
Income taxes and tax credits recoverable
|
8,401
|
4,955
|
||||||
Inventories
|
37,883
|
33,832
|
||||||
Prepaid expenses
|
5,185
|
4,202
|
||||||
Other assets
|
1,776
|
‒
|
||||||
124,477
|
127,236
|
|||||||
Tax credits recoverable
|
47,988
|
38,111
|
||||||
Property, plant and equipment
|
44,661
|
40,132
|
||||||
Intangible assets
|
27,775
|
11,183
|
||||||
Goodwill
|
41,021
|
35,077
|
||||||
Deferred income tax assets
|
4,615
|
6,555
|
||||||
Other assets
|
666
|
947
|
||||||
$
|
291,203
|
$
|
259,241
|
|||||
Liabilities
|
||||||||
Current liabilities
|
||||||||
Bank loan (note 6)
|
$
|
10,982
|
$
|
‒
|
||||
Accounts payable and accrued liabilities
|
50,702
|
36,776
|
||||||
Provisions
|
471
|
3,889
|
||||||
Income taxes payable
|
968
|
663
|
||||||
Deferred revenue
|
17,142
|
11,554
|
||||||
Other liabilities
|
4,651
|
‒
|
||||||
Current portion of long-term debt (note 7)
|
2,938
|
‒
|
||||||
87,854
|
52,882
|
|||||||
Provisions
|
1,510
|
‒
|
||||||
Deferred revenue
|
6,235
|
6,257
|
||||||
Long-term debt (note 7)
|
6,579
|
‒
|
||||||
Deferred income tax liabilities
|
5,074
|
3,116
|
||||||
Other liabilities
|
568
|
196
|
||||||
107,820
|
62,451
|
|||||||
Shareholders' equity
|
||||||||
Share capital (note 8)
|
91,910
|
90,411
|
||||||
Contributed surplus
|
18,007
|
18,184
|
||||||
Retained earnings
|
118,857
|
127,160
|
||||||
Accumulated other comprehensive loss
|
(45,391
|
)
|
(38,965
|
)
|
||||
183,383
|
196,790
|
|||||||
$
|
291,203
|
$
|
259,241
|
Three months
ended
May 31, 2018
|
Nine months
ended
May 31, 2018
|
Three months
ended
May 31, 2017
|
Nine months
ended
May 31, 2017
|
|||||||||||||
Sales
|
$
|
72,217
|
$
|
200,330
|
$
|
58,505
|
$
|
180,320
|
||||||||
Cost of sales (1) (note 9)
|
28,963
|
77,578
|
24,555
|
70,357
|
||||||||||||
Selling and administrative (note 9)
|
25,957
|
74,066
|
22,572
|
65,422
|
||||||||||||
Net research and development (note 9)
|
16,101
|
40,440
|
13,263
|
35,841
|
||||||||||||
Depreciation of property, plant and equipment (note 9)
|
1,555
|
3,972
|
1,029
|
2,894
|
||||||||||||
Amortization of intangible assets (note 9)
|
4,210
|
8,385
|
1,046
|
2,241
|
||||||||||||
Change in fair value of cash contingent consideration (note 5)
|
‒
|
(716
|
)
|
‒
|
‒
|
|||||||||||
Interest and other expense
|
198
|
870
|
57
|
28
|
||||||||||||
Foreign exchange gain
|
(160
|
)
|
(1,386
|
)
|
(1,725
|
)
|
(1,965
|
)
|
||||||||
Share in net loss of an associate (note 3)
|
‒
|
2,080
|
‒
|
‒
|
||||||||||||
Gain on deemed disposal of the investment in an associate (note 3)
|
‒
|
(2,080
|
)
|
‒
|
‒
|
|||||||||||
Earnings (loss) before income taxes
|
(4,607
|
)
|
(2,879
|
)
|
(2,292
|
)
|
5,502
|
|||||||||
Income taxes (note 10)
|
1,363
|
5,424
|
2,012
|
5,495
|
||||||||||||
Net earnings (loss) for the period
|
(5,970
|
)
|
(8,303
|
)
|
(4,304
|
)
|
7
|
|||||||||
Net loss for the period attributable to non-controlling interest
|
‒
|
(352
|
)
|
‒
|
‒
|
|||||||||||
Net earnings (loss) for the period attributable to parent interest
|
$
|
(5,970
|
)
|
$
|
(7,951
|
)
|
$
|
(4,304
|
)
|
$
|
7
|
|||||
Basic and diluted net earnings (loss) attributable to parent interest per share
|
$
|
(0.11
|
)
|
$
|
(0.14
|
)
|
$
|
(0.08
|
)
|
$
|
0.00
|
|||||
Basic weighted average number of shares outstanding (000's)
|
55,099
|
54,959
|
54,593
|
54,328
|
||||||||||||
Diluted weighted average number of shares outstanding (000's) (note 11)
|
55,099
|
54,959
|
54,593
|
55,479
|
(1)
|
The cost of sales is exclusive of depreciation and amortization, shown separately.
|
Three months
ended
May 31, 2018
|
Nine months
ended
May 31, 2018
|
Three months
ended
May 31, 2017
|
Nine months
ended
May 31, 2017
|
|||||||||||||
Net earnings (loss) for the period
|
$
|
(5,970
|
)
|
$
|
(8,303
|
)
|
$
|
(4,304
|
)
|
$
|
7
|
|||||
Other comprehensive income (loss), net of income taxes
|
||||||||||||||||
Items that may be reclassified subsequently to net earnings
|
||||||||||||||||
Foreign currency translation adjustment
|
(3,189
|
)
|
(5,033
|
)
|
(2,568
|
)
|
(4,766
|
)
|
||||||||
Unrealized gains/losses on forward exchange contracts
|
(486
|
)
|
(971
|
)
|
(127
|
)
|
(362
|
)
|
||||||||
Reclassification of realized gains/losses on forward exchange contracts in net earnings
|
(232
|
)
|
(840
|
)
|
39
|
359
|
||||||||||
Deferred income taxes on gains/losses on forward exchange contracts
|
155
|
418
|
39
|
31
|
||||||||||||
Other comprehensive loss
|
(3,752
|
)
|
(6,426
|
)
|
(2,617
|
)
|
(4,738
|
)
|
||||||||
Comprehensive loss for the period
|
(9,722
|
)
|
(14,729
|
)
|
(6,921
|
)
|
(4,731
|
)
|
||||||||
Comprehensive loss for the period attributable to non-controlling interest
|
‒
|
(352
|
)
|
‒
|
‒
|
|||||||||||
Comprehensive loss for the period attributable to parent interest
|
$
|
(9,722
|
)
|
$
|
(14,377
|
)
|
$
|
(6,921
|
)
|
$
|
(4,731
|
)
|
||||
Nine months ended May 31, 2017
|
||||||||||||||||||||
Share
capital |
Contributed
surplus |
Retained
earnings |
Accumulated
other comprehensive loss |
Total
shareholders' equity |
||||||||||||||||
Balance as at September 1, 2016
|
$
|
85,516
|
$
|
18,150
|
$
|
126,309
|
$
|
(48,574
|
)
|
$
|
181,401
|
|||||||||
Issuance of share capital (note 8)
|
3,490
|
–
|
–
|
–
|
3,490
|
|||||||||||||||
Reclassification of stock-based compensation costs (note 8)
|
1,370
|
(1,370
|
)
|
–
|
–
|
–
|
||||||||||||||
Stock-based compensation costs
|
–
|
941
|
–
|
–
|
941
|
|||||||||||||||
Net earnings for the period
|
–
|
–
|
7
|
–
|
7
|
|||||||||||||||
Other comprehensive income (loss)
|
||||||||||||||||||||
Foreign currency translation adjustment
|
–
|
–
|
–
|
(4,766
|
)
|
(4,766
|
)
|
|||||||||||||
Changes in unrealized gains/losses on forward exchange contracts, net of deferred income taxes of $31
|
–
|
–
|
–
|
28
|
28
|
|||||||||||||||
Total comprehensive loss for the period
|
(4,731
|
)
|
||||||||||||||||||
Balance as at May 31, 2017
|
$
|
90,376
|
$
|
17,721
|
$
|
126,316
|
$
|
(53,312
|
)
|
$
|
181,101
|
Nine months ended May 31, 2018
|
||||||||||||||||||||||||
Share
capital
|
Contributed surplus
|
Retained earnings
|
Accumulated other comprehensive loss
|
Non-controlling interest
|
Total
shareholders' equity
|
|||||||||||||||||||
Balance as at September 1, 2017
|
$
|
90,411
|
$
|
18,184
|
$
|
127,160
|
$
|
(38,965
|
)
|
$
|
‒
|
$
|
196,790
|
|||||||||||
Reclassification of stock-based compensation costs (note 8)
|
1,499
|
(1,499
|
)
|
‒
|
‒
|
‒
|
‒
|
|||||||||||||||||
Stock-based compensation costs
|
‒
|
1,322
|
‒
|
‒
|
‒
|
1,322
|
||||||||||||||||||
Business combination (note 3)
|
‒
|
‒
|
‒
|
‒
|
(3,662
|
)
|
(3,662
|
)
|
||||||||||||||||
Acquisition of non-controlling
interest (note 3) |
‒
|
‒
|
(352
|
)
|
‒
|
4,014
|
3,662
|
|||||||||||||||||
Net loss for the period
|
‒
|
‒
|
(7,951
|
)
|
‒
|
(352
|
)
|
(8,303
|
)
|
|||||||||||||||
Other comprehensive loss
|
||||||||||||||||||||||||
Foreign currency translation adjustment
|
‒
|
‒
|
‒
|
(5,033
|
)
|
‒
|
(5,033
|
)
|
||||||||||||||||
Changes in unrealized gains/losses on forward exchange contracts, net of deferred income taxes of $418
|
‒
|
‒
|
‒
|
(1,393
|
)
|
‒
|
(1,393
|
)
|
||||||||||||||||
Comprehensive loss for the period
|
(14,729
|
)
|
||||||||||||||||||||||
Balance as at May 31, 2018
|
$
|
91,910
|
$
|
18,007
|
$
|
118,857
|
$
|
(45,391
|
)
|
$
|
‒
|
$
|
183,383
|
Three months
ended
May 31, 2018
|
Nine months
ended
May 31, 2018
|
Three months
ended
May 31, 2017
|
Nine months
ended
May 31, 2017
|
|||||||||||||
Cash flows from operating activities
|
||||||||||||||||
Net earnings (loss) for the period
|
$
|
(5,970
|
)
|
$
|
(8,303
|
)
|
$
|
(4,304
|
)
|
$
|
7
|
|||||
Add (deduct) items not affecting cash
|
||||||||||||||||
Stock-based compensation costs
|
440
|
1,280
|
372
|
983
|
||||||||||||
Depreciation and amortization
|
5,765
|
12,357
|
2,075
|
5,135
|
||||||||||||
Write-off of capital assets
|
77
|
325
|
‒
|
‒
|
||||||||||||
Change in fair value of cash contingent consideration
|
‒
|
(716
|
)
|
‒
|
‒
|
|||||||||||
Deferred revenue
|
(552
|
)
|
1,682
|
79
|
3,026
|
|||||||||||
Deferred income taxes
|
389
|
2,533
|
704
|
1,163
|
||||||||||||
Share in net loss of an associate
|
‒
|
2,080
|
‒
|
‒
|
||||||||||||
Gain on deemed disposal of the investment in an associate
|
‒
|
(2,080
|
)
|
‒
|
‒
|
|||||||||||
Changes in foreign exchange gain/loss
|
(603
|
)
|
(239
|
)
|
(524
|
)
|
(955
|
)
|
||||||||
(454
|
)
|
8,919
|
(1,598
|
)
|
9,359
|
|||||||||||
Changes in non-cash operating items
|
||||||||||||||||
Accounts receivable
|
2,353
|
7,693
|
(901
|
)
|
1,701
|
|||||||||||
Income taxes and tax credits
|
172
|
(2,787
|
)
|
(842
|
)
|
(1,232
|
)
|
|||||||||
Inventories
|
1,162
|
(12
|
)
|
315
|
(9
|
)
|
||||||||||
Prepaid expenses
|
16
|
205
|
(863
|
)
|
(761
|
)
|
||||||||||
Other assets
|
(245
|
)
|
(769
|
)
|
(103
|
)
|
(127
|
)
|
||||||||
Accounts payable, accrued liabilities and provisions
|
1,821
|
5
|
1,169
|
1,756
|
||||||||||||
Other liabilities
|
(109
|
)
|
101
|
‒
|
‒
|
|||||||||||
4,716
|
13,355
|
(2,823
|
)
|
10,687
|
||||||||||||
Cash flows from investing activities
|
||||||||||||||||
Additions to short-term investments
|
‒
|
(482
|
)
|
(2,571
|
)
|
(2,887
|
)
|
|||||||||
Proceeds from disposal and maturity of short-term investments
|
‒
|
234
|
3,298
|
3,596
|
||||||||||||
Purchases of capital assets
|
(3,431
|
)
|
(7,680
|
)
|
(2,555
|
)
|
(5,448
|
)
|
||||||||
Investment in an associate (note 3)
|
‒
|
(12,530
|
)
|
–
|
–
|
|||||||||||
Business combinations, net of cash
acquired (note 3) |
‒
|
(19,120
|
)
|
(7,479
|
)
|
(12,479
|
)
|
|||||||||
(3,431
|
)
|
(39,578
|
)
|
(9,307
|
)
|
(17,218
|
)
|
|||||||||
Cash flows from financing activities
|
||||||||||||||||
Bank loan
|
9,184
|
11,250
|
–
|
–
|
||||||||||||
Repayment of long-term debt
|
(757
|
)
|
(1,027
|
)
|
(1,480
|
)
|
(1,480
|
)
|
||||||||
Acquisition of non-controlling interest (note 3)
|
(3,657
|
)
|
(3,657
|
)
|
–
|
–
|
||||||||||
4,770
|
6,566
|
(1,480
|
)
|
(1,480
|
)
|
|||||||||||
Effect of foreign exchange rate changes on cash
|
(119
|
)
|
(289
|
)
|
(360
|
)
|
(824
|
)
|
||||||||
Change in cash during the period
|
5,936
|
(19,946
|
)
|
(13,970
|
)
|
(8,835
|
)
|
|||||||||
Cash – Beginning of the period
|
12,553
|
38,435
|
48,343
|
43,208
|
||||||||||||
Cash – End of the period
|
$
|
18,489
|
$
|
18,489
|
$
|
34,373
|
$
|
34,373
|
||||||||
Supplementary information
|
||||||||||||||||
Income taxes paid
|
$
|
426
|
$
|
1,695
|
$
|
627
|
$
|
2,188
|
||||||||
Additions to capital assets
|
$
|
3,371
|
$
|
8,959
|
$
|
1,779
|
$
|
5,441
|
1
|
Nature of Activities and Incorporation
|
2
|
Basis of Presentation
|
3
|
Business Combinations
|
Three months
ended
May 31, 2018
|
Nine months
ended
May 31, 2018
|
|||||||
Sales (1)
|
$
|
8,595
|
$
|
10,427
|
||||
Net loss attributable to the parent interest (1,2)
|
$
|
6,336
|
$
|
8,987
|
(1)
|
Include acquisition-related deferred revenue fair value adjustment of $913,000 and $1,222,000 respectively for the three months and the nine months ended May 31, 2018.
|
(2)
|
Includes amortization of acquired intangible assets of $3,104,000 and $4,154,000 respectively for the three months and the nine months ended May 31, 2018.
|
Assets acquired
|
||||
Accounts receivable
|
$
|
15,877
|
||
Income taxes and tax credits recoverable
|
11,259
|
|||
Inventories
|
3,045
|
|||
Prepaid expenses
|
1,229
|
|||
Property, plant and equipment
|
1,944
|
|||
Intangible assets
|
19,150
|
|||
Other assets
|
1,402
|
|||
53,906
|
||||
Liabilities assumed
|
||||
Accounts payable and accrued liabilities
|
10,571
|
|||
Deferred revenue
|
4,748
|
|||
Long-term debt (note 7)
|
8,888
|
|||
Other liabilities
|
6,715
|
|||
Net identifiable assets acquired
|
22,984
|
|||
Goodwill
|
3,257
|
|||
Fair value of the total consideration, net of cash acquired
|
$
|
26,241
|
Cash paid net of cash acquired
|
$
|
9,580
|
||
Fair value of shares held
|
12,967
|
|||
Non-controlling interest (purchased in February 2018)
|
3,694
|
|||
$
|
26,241
|
Assets acquired
|
||||
Accounts receivable
|
$
|
1,889
|
||
Inventories
|
2,384
|
|||
Property, plant and equipment
|
1,424
|
|||
Core technologies
|
3,686
|
|||
Customer relationships
|
811
|
|||
In-process research and development
|
305
|
|||
Other intangible assets
|
132
|
|||
Prepaid expenses
|
171
|
|||
10,802
|
||||
Liabilities assumed
|
||||
Accounts payable and accrued liabilities
|
1,035
|
|||
Long-term debt (note 7)
|
2,143
|
|||
Deferred income taxes
|
1,510
|
|||
Net identifiable assets acquired
|
6,114
|
|||
Goodwill
|
3,426
|
|||
Fair value of the total consideration, net of cash acquired
|
$
|
9,540
|
Three months
ended
May 31, 2018
|
Nine months
ended
May 31, 2018
|
|||||||
Balance – Beginning of the period
|
$
|
41,725
|
$
|
35,077
|
||||
Business combinations
|
‒
|
6,683
|
||||||
Foreign currency translation adjustment
|
(704
|
)
|
(739
|
)
|
||||
Balance – End of the period
|
$
|
41,021
|
$
|
41,021
|
4
|
Restructuring Charges
|
Three months
ended
May 31, 2018
|
Nine months
ended
May 31, 2018
|
|||||||
Balance – Beginning of the period
|
$
|
190
|
$
|
2,477
|
||||
Payments
|
(58
|
)
|
(1,970
|
)
|
||||
Reversal
|
(92
|
)
|
(467
|
)
|
||||
Balance – End of the period
|
$
|
40
|
$
|
40
|
5
|
Financial Instruments
|
Level 1: |
Quoted prices (unadjusted) in active markets for identical assets or liabilities
|
Level 2: |
Inputs other than quoted prices included within Level 1 that are observable for the asset and liability, either directly or indirectly
|
Level 3: |
Unobservable inputs for the asset or liability
|
As at May 31, 2018
|
As at August 31, 2017
|
|||||||||||||||||||||||
Level 1
|
Level 2
|
Level 3
|
Level 1
|
Level 2
|
Level 3
|
|||||||||||||||||||
Financial assets
|
||||||||||||||||||||||||
Short-term investments
|
$
|
990
|
$
|
‒
|
$
|
‒
|
$
|
775
|
$
|
‒
|
$
|
‒
|
||||||||||||
Forward exchange contracts
|
$
|
‒
|
$
|
667
|
$
|
‒
|
$
|
‒
|
$
|
2,258
|
$
|
‒
|
||||||||||||
Financial liabilities
|
||||||||||||||||||||||||
Contingent liability
|
$
|
‒
|
$
|
‒
|
$
|
437
|
$
|
‒
|
$
|
‒
|
$
|
1,092
|
||||||||||||
Forward exchange contracts
|
$
|
‒
|
$
|
432
|
$
|
‒
|
$
|
‒
|
$
|
‒
|
$
|
‒
|
Expiry dates
|
Contractual
amounts
|
Weighted average
contractual forward rates
|
|||||||
June 2018 to August 2018
|
$
|
7,500
|
1.3160
|
||||||
September 2018 to August 2019
|
24,000
|
1.3026
|
|||||||
September 2019 to August 2020
|
12,100
|
1.2707
|
|||||||
September 2020 to January 2021
|
1,700
|
1.2584
|
|||||||
Total
|
$
|
45,300
|
1.2946
|
Expiry dates
|
Contractual
amounts
|
Weighted average
contractual forward rates
|
|||||||
June 2018 to August 2018
|
$
|
600
|
68.04
|
||||||
September 2018 to August 2019
|
4,600
|
67.68
|
|||||||
Total
|
$
|
5,200
|
67.72
|
Three months
ended
May 31, 2018
|
Nine months
ended
May 31, 2018
|
Three months
ended
May 31, 2017
|
Nine months
ended
May 31, 2017
|
|||||||||||||
Gains (losses) on forward exchange contracts
|
$
|
179
|
$
|
797
|
$
|
(180
|
)
|
$
|
(525
|
)
|
6
|
Credit Facilities
|
7
|
Long-term Debt
|
As at
May 31,
2018
|
As at
August 31,
2017
|
|||||||
Unsecured, non-interest-bearing loans, denominated in euros, repayable in quarterly instalments, maturing in March 2024 and March 2025
|
$
|
872
|
$
|
‒
|
||||
Unsecured loans, denominated in euros, repayable in monthly, quarterly or bi-annual instalments, bearing interest at annual rates of nil to 5.0%, maturing at different dates between December 2018 and September 2023
|
5,196
|
‒
|
||||||
Loans, secured by the universality of the assets of a subsidiary, denominated in euros, repayable in monthly instalments, bearing interest at annual rates of 0.7% to 2.0%, maturing at different dates between June 2019 and August 2022
|
909
|
‒
|
||||||
Loans, secured by the universality of the assets of a subsidiary, denominated in euros, repayable in monthly or quarterly instalments, bearing interest at annual rates of 1.1% to 2.9%, maturing at different dates between March 2020 and July 2022
|
2,491
|
‒
|
||||||
Other long-term debt
|
49
|
‒
|
||||||
9,517
|
‒
|
|||||||
Current portion of long-term debt
|
2,938
|
‒
|
||||||
$
|
6,579
|
$
|
‒
|
As at
May 31, 2018
|
||||
No later than one year
|
$
|
2,938
|
||
Later than one year and no later than five years
|
6,262
|
|||
Later than five years
|
317
|
|||
$
|
9,517
|
8
|
Share Capital
|
Nine months ended May 31, 2017
|
||||||||||||||||||||
Multiple voting shares
|
Subordinate voting shares
|
|||||||||||||||||||
Number
|
Amount
|
Number
|
Amount
|
Total
amount
|
||||||||||||||||
Balance as at September 1, 2016
|
31,643,000
|
$
|
1
|
21,917,942
|
$
|
85,515
|
$
|
85,516
|
||||||||||||
Issuance of share capital
|
−
|
−
|
793,070
|
3,490
|
3,490
|
|||||||||||||||
Redemption of restricted share units
|
−
|
−
|
88,371
|
−
|
−
|
|||||||||||||||
Reclassification of stock-based compensation costs to share capital upon exercise of stock awards
|
−
|
−
|
−
|
346
|
346
|
|||||||||||||||
Balance as at November 30, 2016
|
31,643,000
|
1
|
22,799,383
|
89,351
|
89,352
|
|||||||||||||||
Redemption of restricted share units
|
−
|
−
|
97,900
|
−
|
−
|
|||||||||||||||
Redemption of deferred share units
|
−
|
−
|
29,456
|
−
|
−
|
|||||||||||||||
Reclassification of stock-based compensation costs to share capital upon exercise of stock awards
|
−
|
−
|
−
|
489
|
489
|
|||||||||||||||
Balance as at February 28, 2017
|
31,643,000
|
1
|
22,926,739
|
89,840
|
89,841
|
|||||||||||||||
Redemption of restricted share units
|
−
|
−
|
132,422
|
−
|
−
|
|||||||||||||||
Redemption of deferred share units
|
−
|
−
|
450
|
−
|
−
|
|||||||||||||||
Reclassification of stock-based compensation costs to share capital upon exercise of stock awards
|
−
|
−
|
−
|
535
|
535
|
|||||||||||||||
Balance as at May 31, 2017
|
31,643,000
|
$
|
1
|
23,059,611
|
$
|
90,375
|
$
|
90,376
|
Nine months ended May 31, 2018
|
||||||||||||||||||||
Multiple voting shares
|
Subordinate voting shares
|
|||||||||||||||||||
Number
|
Amount
|
Number
|
Amount
|
Total
amount
|
||||||||||||||||
Balance as at September 1, 2017
|
31,643,000
|
$
|
1
|
23,068,777
|
$
|
90,410
|
$
|
90,411
|
||||||||||||
Redemption of restricted share units
|
−
|
−
|
155,619
|
−
|
−
|
|||||||||||||||
Reclassification of stock-based compensation costs to share capital upon exercise of stock awards
|
−
|
−
|
−
|
598
|
598
|
|||||||||||||||
Balance as at November 30, 2017
|
31,643,000
|
1
|
23,224,396
|
91,008
|
91,009
|
|||||||||||||||
Redemption of restricted share units
|
−
|
−
|
182,725
|
−
|
−
|
|||||||||||||||
Reclassification of stock-based compensation costs to share capital upon exercise of stock awards
|
−
|
−
|
−
|
675
|
675
|
|||||||||||||||
Balance as at February 28, 2018
|
31,643,000
|
1
|
23,407,121
|
91,683
|
91,684
|
|||||||||||||||
Redemption of deferred share units
|
−
|
−
|
58,335
|
−
|
−
|
|||||||||||||||
Reclassification of stock-based compensation costs to share capital upon exercise of stock awards
|
−
|
−
|
−
|
226
|
226
|
|||||||||||||||
Balance as at May 31, 2018
|
31,643,000
|
$
|
1
|
23,465,456
|
$
|
91,909
|
$
|
91,910
|
9
|
Statements of Earnings
|
Three months
ended
May 31, 2018
|
Nine months
ended
May 31, 2018
|
Three months
ended
May 31, 2017
|
Nine months
ended
May 31, 2017
|
|||||||||||||
Gross research and development expenses
|
$
|
18,393
|
$
|
46,636
|
$
|
14,710
|
$
|
40,067
|
||||||||
Research and development tax credits and grants
|
(2,292
|
)
|
(6,196
|
)
|
(1,447
|
)
|
(4,226
|
)
|
||||||||
Net research and development expenses for the period
|
$
|
16,101
|
$
|
40,440
|
$
|
13,263
|
$
|
35,841
|
Three months
ended
May 31, 2018
|
Nine months
ended
May 31, 2018
|
Three months
ended
May 31, 2017
|
Nine months
ended
May 31, 2017
|
|||||||||||||
Inventory write-down for the period
|
$
|
681
|
$
|
1,950
|
$
|
1,464
|
$
|
2,440
|
Three months
ended May 31, 2018 |
Nine months
ended May 31, 2018 |
Three months
ended May 31, 2017 |
Nine months
ended May 31, 2017 |
|||||||||||||
Cost of sales
|
||||||||||||||||
Depreciation of property, plant and equipment
|
$
|
583
|
$
|
1,521
|
$
|
374
|
$
|
1,104
|
||||||||
Amortization of intangible assets
|
3,879
|
7,606
|
927
|
1,896
|
||||||||||||
4,462
|
9,127
|
1,301
|
3,000
|
|||||||||||||
Selling and administrative expenses
|
||||||||||||||||
Depreciation of property, plant and equipment
|
280
|
647
|
130
|
387
|
||||||||||||
Amortization of intangible assets
|
174
|
421
|
23
|
59
|
||||||||||||
454
|
1,068
|
153
|
446
|
|||||||||||||
Net research and development expenses
|
||||||||||||||||
Depreciation of property, plant and equipment
|
692
|
1,804
|
525
|
1,403
|
||||||||||||
Amortization of intangible assets
|
157
|
358
|
96
|
286
|
||||||||||||
849
|
2,162
|
621
|
1,689
|
|||||||||||||
$
|
5,765
|
$
|
12,357
|
$
|
2,075
|
$
|
5,135
|
|||||||||
Depreciation of property, plant and equipment
|
$
|
1,555
|
$
|
3,972
|
$
|
1,029
|
$
|
2,894
|
||||||||
Amortization of intangible assets
|
4,210
|
8,385
|
1,046
|
2,241
|
||||||||||||
Total depreciation and amortization expenses for the period
|
$
|
5,765
|
$
|
12,357
|
$
|
2,075
|
$
|
5,135
|
Three months
ended May 31, 2018 |
Nine months
ended May 31, 2018 |
Three months
ended May 31, 2017 |
Nine months
ended May 31, 2017 |
|||||||||||||
Salaries and benefits
|
$
|
38,699
|
$
|
101,848
|
$
|
30,565
|
$
|
88,587
|
||||||||
Restructuring charges
|
−
|
−
|
2,783
|
2,783
|
||||||||||||
Stock-based compensation costs
|
440
|
1,280
|
372
|
983
|
||||||||||||
Total employee compensation for the period
|
$
|
39,139
|
$
|
103,128
|
$
|
33,720
|
$
|
92,353
|
Three months
ended May 31, 2018 |
Nine months
ended May 31, 2018 |
Three months
ended May 31, 2017 |
Nine months
ended May 31, 2017 |
|||||||||||||
Cost of sales (1)
|
$
|
‒
|
$
|
‒
|
$
|
1,582
|
$
|
1,582
|
||||||||
Selling and administrative expenses
|
‒
|
‒
|
919
|
919
|
||||||||||||
Net research and development expenses
|
‒
|
‒
|
1,312
|
1,312
|
||||||||||||
Total restructuring charges for the period
|
$
|
‒
|
$
|
‒
|
$
|
3,813
|
$
|
3,813
|
(1)
|
Includes $1,030,000 in inventory write-off.
|
Three months
ended May 31, 2018 |
Nine months
ended May 31, 2018 |
Three months
ended May 31, 2017 |
Nine months
ended May 31, 2017 |
|||||||||||||
Cost of sales
|
$
|
36
|
$
|
107
|
$
|
33
|
$
|
87
|
||||||||
Selling and administrative expenses
|
297
|
882
|
251
|
681
|
||||||||||||
Net research and development expenses
|
107
|
291
|
88
|
215
|
||||||||||||
Total stock-based compensation for the period
|
$
|
440
|
$
|
1,280
|
$
|
372
|
$
|
983
|
10
|
Income Taxes
|
Three months
ended May 31, 2018 |
Nine months
ended May 31, 2018 |
Three months
ended May 31, 2017 |
Nine months
ended May 31, 2017 |
|||||||||||||
Income tax provision (recovery) at combined Canadian federal and provincial statutory tax rate (27%)
|
$
|
(1,244
|
)
|
$
|
(777
|
)
|
$
|
(619
|
)
|
$
|
1,486
|
|||||
Increase (decrease) due to:
|
||||||||||||||||
Foreign income taxed at different rates
|
44
|
(26
|
)
|
(60
|
)
|
(640
|
)
|
|||||||||
Non-deductible loss (non-taxable income)
|
147
|
(60
|
)
|
(226
|
)
|
(37
|
)
|
|||||||||
Non-deductible expenses
|
239
|
1,189
|
225
|
578
|
||||||||||||
Change in tax rates
|
‒
|
167
|
15
|
(10
|
)
|
|||||||||||
Effect of the US tax reform
|
‒
|
1,528
|
‒
|
‒
|
||||||||||||
Foreign exchange effect of translation of foreign subsidiaries in the functional currency
|
(131
|
)
|
(366
|
)
|
27
|
(91
|
)
|
|||||||||
Utilization of previously unrecognized deferred income tax assets
|
(112
|
)
|
(394
|
)
|
234
|
(55
|
)
|
|||||||||
Unrecognized deferred income tax assets on temporary deductible differences and unused tax losses
|
2,411
|
4,744
|
2,222
|
4,202
|
||||||||||||
Other
|
9
|
(581
|
)
|
194
|
62
|
|||||||||||
Income tax provision for the period
|
$
|
1,363
|
$
|
5,424
|
$
|
2,012
|
$
|
5,495
|
Three months
ended May 31, 2018 |
Nine months
ended May 31, 2018 |
Three months
ended May 31, 2017 |
Nine months
ended May 31, 2017 |
|||||||||||||
Current
|
$
|
974
|
$
|
2,891
|
$
|
1,308
|
$
|
4,332
|
||||||||
Deferred
|
389
|
2,533
|
704
|
1,163
|
||||||||||||
$
|
1,363
|
$
|
5,424
|
$
|
2,012
|
$
|
5,495
|
11
|
Earnings per Share
|
Three months
ended May 31, 2018 |
Nine months
ended May 31, 2018 |
Three months
ended May 31, 2017 |
Nine months
ended May 31, 2017 |
|||||||||||||
Basic weighted average number of shares outstanding (000's)
|
55,099
|
54,959
|
54,593
|
54,328
|
||||||||||||
Plus dilutive effect of (000's):
|
||||||||||||||||
Restricted share units
|
602
|
727
|
1,018
|
999
|
||||||||||||
Deferred share units
|
158
|
174
|
145
|
152
|
||||||||||||
Diluted weighted average number of shares outstanding (000's)
|
55,859
|
55,860
|
55,756
|
55,479
|
||||||||||||
Stock awards excluded from the calculation of diluted weighted average number of shares because their exercise price was greater than the average market price of the common shares (000's)
|
194
|
109
|
–
|
–
|
Three months
ended
May 31, 2018
|
Three months
ended
May 31, 2017
|
Nine months
ended
May 31, 2018
|
Nine months
ended
May 31, 2017
|
|||||||||||||
Sales
|
$
|
72,217
|
$
|
58,505
|
$
|
200,330
|
$
|
180,320
|
||||||||
Cost of sales (1)
|
28,963
|
24,555
|
77,578
|
70,357
|
||||||||||||
Selling and administrative
|
25,957
|
22,572
|
74,066
|
65,422
|
||||||||||||
Net research and development
|
16,101
|
13,263
|
40,440
|
35,841
|
||||||||||||
Depreciation of property, plant and equipment
|
1,555
|
1,029
|
3,972
|
2,894
|
||||||||||||
Amortization of intangible assets
|
4,210
|
1,046
|
8,385
|
2,241
|
||||||||||||
Change in fair value of cash contingent consideration
|
‒
|
‒
|
(716
|
)
|
‒
|
|||||||||||
Interest and other expense
|
198
|
57
|
870
|
28
|
||||||||||||
Foreign exchange gain
|
(160
|
)
|
(1,725
|
)
|
(1,386
|
)
|
(1,965
|
)
|
||||||||
Share in net loss of an associate
|
‒
|
‒
|
2,080
|
‒
|
||||||||||||
Gain on the deemed disposal of the investment in an associate
|
‒
|
‒
|
(2,080
|
)
|
‒
|
|||||||||||
Earnings (loss) before income taxes
|
(4,607
|
)
|
(2,292
|
)
|
(2,879
|
)
|
5,502
|
|||||||||
Income taxes
|
1,363
|
2,012
|
5,424
|
5,495
|
||||||||||||
Net earnings (loss) for the period
|
(5,970
|
)
|
(4,304
|
)
|
(8,303
|
)
|
7
|
|||||||||
Net loss for the period attributable to non-controlling interest
|
‒
|
‒
|
(352
|
)
|
‒
|
|||||||||||
Net earnings (loss) for the period attributable to parent interest (2)
|
$
|
(5,970
|
)
|
$
|
(4,304
|
)
|
$
|
(7,951
|
)
|
$
|
7
|
|||||
Basic and diluted net earnings (loss) attributable to parent interest per share
|
$
|
(0.11
|
)
|
$
|
(0.08
|
)
|
$
|
(0.14
|
)
|
$
|
0.00
|
|||||
Other selected information:
|
||||||||||||||||
Non-IFRS sales (3)
|
$
|
73,130
|
$
|
58,505
|
$
|
201,552
|
$
|
180,320
|
||||||||
Gross margin before depreciation and amortization (3)
|
$
|
43,254
|
$
|
33,950
|
$
|
122,752
|
$
|
109,963
|
||||||||
Research and development:
|
||||||||||||||||
Gross research and development
|
$
|
18,393
|
$
|
14,710
|
$
|
46,636
|
$
|
40,067
|
||||||||
Net research and development
|
$
|
16,101
|
$
|
13,263
|
$
|
40,440
|
$
|
35,841
|
||||||||
Restructuring charges included in:
|
||||||||||||||||
Cost of sales
|
$
|
‒
|
$
|
1,582
|
$
|
‒
|
$
|
1,582
|
||||||||
Selling and administrative
|
$
|
‒
|
$
|
919
|
$
|
‒
|
$
|
919
|
||||||||
Net research and development
|
$
|
‒
|
$
|
1,312
|
$
|
‒
|
$
|
1,312
|
||||||||
Adjusted EBITDA (3)(4)(5)
|
$
|
2,549
|
$
|
2,300
|
$
|
11,100
|
$
|
13,496
|
(1)
|
The cost of sales is exclusive of depreciation and amortization, shown separately.
|
(2)
|
Includes net loss of Astellia of $6.3 million and $9.0 million respectively for the three and nine months ended May 31, 2018 (nil in 2017).
|
(3)
|
Refer to page 51 for non-IFRS measures.
|
(4)
|
Astellia negatively impacted the adjusted EBITDA by $2.2 million and $3.4 million respectively for the three and nine months ended May 31, 2018 (nil in 2017).
|
(5)
|
Includes acquisition-related costs of $2.1 million for the nine months ended May 31, 2018 and $0.1 million and $0.8 million respectively for the three and nine months ended May 31, 2017.
|
Three months
ended
May 31, 2018
|
Three months
ended
May 31, 2017
|
Nine months
ended
May 31, 2018
|
Nine months
ended
May 31, 2017
|
|||||||||||||
Sales
|
100.0
|
%
|
100.0
|
%
|
100.0
|
%
|
100.0
|
%
|
||||||||
Cost of sales (1)
|
40.1
|
42.0
|
38.7
|
39.0
|
||||||||||||
Selling and administrative
|
35.9
|
38.6
|
37.0
|
36.3
|
||||||||||||
Net research and development
|
22.3
|
22.7
|
20.2
|
19.9
|
||||||||||||
Depreciation of property, plant and equipment
|
2.2
|
1.8
|
2.0
|
1.6
|
||||||||||||
Amortization of intangible assets
|
5.8
|
1.8
|
4.2
|
1.2
|
||||||||||||
Change in fair value of cash contingent consideration
|
‒
|
‒
|
(0.4
|
)
|
‒
|
|||||||||||
Interest and other expense
|
0.3
|
‒
|
0.4
|
‒
|
||||||||||||
Foreign exchange gain
|
(0.2
|
)
|
(3.0
|
)
|
(0.7
|
)
|
(1.1
|
)
|
||||||||
Share in net loss of an associate
|
‒
|
‒
|
1.0
|
‒
|
||||||||||||
Gain on the deemed disposal of the investment in an associate
|
‒
|
‒
|
(1.0
|
)
|
‒
|
|||||||||||
Earnings (loss) before income taxes
|
(6.4
|
)
|
(3.9
|
)
|
(1.4
|
)
|
3.1
|
|||||||||
Income taxes
|
1.9
|
3.5
|
2.7
|
3.1
|
||||||||||||
Net earnings (loss) for the period
|
(8.3
|
)
|
(7.4
|
)
|
(4.1
|
)
|
‒
|
|||||||||
Net loss for the period attributable to non-controlling interest
|
–
|
–
|
(0.1
|
)
|
–
|
|||||||||||
Net earnings (loss) for the period attributable to parent interest (2)
|
(8.3
|
)%
|
(7.4
|
)%
|
(4.0
|
)%
|
–
|
%
|
||||||||
Other selected information:
|
||||||||||||||||
Gross margin before depreciation and amortization (3)
|
59.9
|
%
|
58.0
|
%
|
61.3
|
%
|
61.0
|
%
|
||||||||
Research and development:
|
||||||||||||||||
Gross research and development
|
25.5
|
%
|
25.1
|
%
|
23.3
|
%
|
22.2
|
%
|
||||||||
Net research and development
|
22.3
|
%
|
22.7
|
%
|
20.2
|
%
|
19.9
|
%
|
||||||||
Restructuring charges included in:
|
||||||||||||||||
Cost of sales
|
‒
|
%
|
2.7
|
%
|
‒
|
%
|
0.9
|
%
|
||||||||
Selling and administrative
|
‒
|
%
|
1.6
|
%
|
‒
|
%
|
0.5
|
%
|
||||||||
Net research and development
|
‒
|
%
|
2.2
|
%
|
‒
|
%
|
0.7
|
%
|
||||||||
Adjusted EBITDA (3)(4)(5)
|
3.5
|
%
|
3.9
|
%
|
5.5
|
%
|
7.5
|
%
|
(1)
|
The cost of sales is exclusive of depreciation and amortization, shown separately.
|
(2)
|
Includes net loss of Astellia of 8.8% and 4.5% of sales respectively for the three and nine months ended May 31, 2018 (nil in 2017).
|
(3)
|
Refer to page 51 for non-IFRS measures.
|
(4)
|
Astellia negatively impacted the adjusted EBITDA by 3.0% and 1.7% of sales respectively for the three and nine months ended May 31, 2018 (nil in 2017).
|
(5)
|
Includes acquisition-related costs of 1.0% of sales for the nine months ended May 31, 2018 and 0.2% and 0.4% of sales respectively for the three and nine months ended May 31, 2017.
|
Three months
ended
May 31, 2018
|
Three months
ended
May 31, 2017
|
Nine months
ended
May 31, 2018
|
Nine months
ended
May 31, 2017
|
|||||||||||||
Physical-layer product line
|
$
|
43,760
|
$
|
41,007
|
$
|
129,734
|
$
|
121,061
|
||||||||
Protocol-layer product line
|
28,278
|
17,678
|
69,799
|
59,784
|
||||||||||||
72,038
|
58,685
|
199,533
|
180,845
|
|||||||||||||
Foreign exchange gains (losses) on forward exchange contracts
|
179
|
(180
|
)
|
797
|
(525
|
)
|
||||||||||
Total sales
|
$
|
72,217
|
$
|
58,505
|
$
|
200,330
|
$
|
180,320
|
Three months
ended
May 31, 2018
|
Three months
ended
May 31, 2017
|
Nine months
ended
May 31, 2018
|
Nine months
ended
May 31, 2017
|
|||||||||||||
Physical-layer product line
|
$
|
44,796
|
$
|
47,157
|
$
|
134,579
|
$
|
125,278
|
||||||||
Protocol-layer product line
|
28,115
|
16,691
|
69,179
|
60,692
|
||||||||||||
72,911
|
63,848
|
203,758
|
185,970
|
|||||||||||||
Foreign exchange gains (losses) on forward exchange contracts
|
179
|
(180
|
)
|
797
|
(525
|
)
|
||||||||||
Total bookings
|
$
|
73,090
|
$
|
63,668
|
$
|
204,555
|
$
|
185,445
|
Three months
ended
May 31, 2018
|
Three months
ended
May 31, 2017
|
Nine months
ended
May 31, 2018
|
Nine months
ended
May 31, 2017
|
|||||||||||||
Americas
|
49
|
%
|
62
|
%
|
50
|
%
|
56
|
%
|
||||||||
EMEA
|
35
|
20
|
31
|
24
|
||||||||||||
Asia-Pacific
|
16
|
18
|
19
|
20
|
||||||||||||
100
|
%
|
100
|
%
|
100
|
%
|
100
|
%
|
Cash flows provided by operating activities
|
$
|
4,716
|
||
Bank loan
|
9,184
|
|||
Acquisition of Astellia (non-controlling interest)
|
(3,657
|
)
|
||
Purchases of capital assets
|
(3,431
|
)
|
||
Repayment of long-term debt
|
(757
|
)
|
||
Unrealized foreign exchange loss on cash and short-term investments
|
(151
|
)
|
||
$
|
5,904
|
Long-term
debt
|
Operating
leases
|
Licensing
agreements
|
Total
|
|||||||||||||
No later than one year
|
$
|
2,938
|
$
|
4,064
|
$
|
1,491
|
$
|
8,493
|
||||||||
Later than one year and no later than five years
|
6,262
|
10,746
|
2,639
|
19,647
|
||||||||||||
Later than five years
|
317
|
1,008
|
‒
|
1,325
|
||||||||||||
$
|
9,517
|
$
|
15,818
|
$
|
4,130
|
$
|
29,465
|
Expiry dates
|
Contractual
amounts
|
Weighted average
contractual
forward rates
|
||||||
June 2018 to August 2018
|
$
|
7,500,000
|
1.3160
|
|||||
September 2018 to August 2019
|
24,000,000
|
1.3026
|
||||||
September 2019 to August 2020
|
12,100,000
|
1.2707
|
||||||
September 2020 to January 2021
|
1,700,000
|
1.2584
|
||||||
Total
|
$
|
45,300,000
|
1.2946
|
Expiry dates
|
Contractual
amounts
|
Weighted average
contractual
forward rates
|
||||||
June 2018 to August 2018
|
$
|
600,000
|
68.04
|
|||||
September 2018 to August 2019
|
4,600,000
|
67.68
|
||||||
Total
|
$
|
5,200,000
|
67.72
|
Three months
ended
May 31, 2018
|
Three months
ended
May 31, 2017
|
Nine months
ended
May 31, 2018
|
Nine months
ended
May 31, 2017
|
|||||||||||||
IFRS sales
|
$
|
72,217
|
$
|
58,505
|
$
|
200,330
|
$
|
180,320
|
||||||||
Acquisition-related deferred revenue fair value adjustment
|
913
|
–
|
1,222
|
–
|
||||||||||||
Non-IFRS sales
|
$
|
73,130
|
$
|
58,505
|
$
|
201,552
|
$
|
180,320
|
Three months
ended
May 31, 2018
|
Three months
ended
May 31, 2017
|
Nine months
ended
May 31, 2018
|
Nine months
ended
May 31, 2017
|
|||||||||||||
IFRS net earnings (loss) attributable to the parent interest for the period
|
$
|
(5,970
|
)
|
$
|
(4,304
|
)
|
$
|
(7,951
|
)
|
$
|
7
|
|||||
Add (deduct):
|
||||||||||||||||
Depreciation of property, plant and equipment
|
1,555
|
1,029
|
3,972
|
2,894
|
||||||||||||
Amortization of intangible assets
|
4,210
|
1,046
|
8,385
|
2,241
|
||||||||||||
Interest and other expense
|
198
|
57
|
870
|
28
|
||||||||||||
Income taxes
|
1,363
|
2,012
|
5,424
|
5,495
|
||||||||||||
Stock-based compensation costs
|
440
|
372
|
1,280
|
983
|
||||||||||||
Restructuring charges
|
–
|
3,813
|
–
|
3,813
|
||||||||||||
Change in fair value of cash contingent consideration
|
–
|
–
|
(716
|
)
|
–
|
|||||||||||
Acquisition-related deferred revenue fair value adjustment
|
913
|
–
|
1,222
|
–
|
||||||||||||
Share in net loss of an associate
|
–
|
–
|
2,080
|
–
|
||||||||||||
Gain on deemed disposal of the investment in an associate
|
–
|
–
|
(2,080
|
)
|
–
|
|||||||||||
Foreign exchange gain
|
(160
|
)
|
(1,725
|
)
|
(1,386
|
)
|
(1,965
|
)
|
||||||||
Adjusted EBITDA for the period (1)(2)
|
$
|
2,549
|
$
|
2,300
|
$
|
11,100
|
$
|
13,496
|
||||||||
Adjusted EBITDA as a percentage of sales
|
3.5
|
%
|
3.9
|
%
|
5.5
|
%
|
7.5
|
%
|
(1)
|
Astellia negatively impacted adjusted EBITDA by $2.2 million and $3.4 million respectively for the three and nine months ended May 31, 2018 (nil in 2017).
|
(2)
|
Include acquisition-related costs of $2.1 million for the nine months ended May 31, 2018 and $0.1 million and $0.8 million respectively for the three and nine months ended May 31, 2017.
|
Quarters ended
|
||||||||||||||||
May 31,
2018
|
February 28,
2018
|
November 30,
2017
|
August 31,
2017
|
|||||||||||||
Sales
|
$
|
72,217
|
$
|
64,722
|
$
|
63,391
|
$
|
62,981
|
||||||||
Cost of sales (1)
|
$
|
28,963
|
$
|
25,326
|
$
|
23,289
|
$
|
23,972
|
||||||||
Net earnings (loss) attributable to the parent interest
|
$
|
(5,970
|
)
|
$
|
(4,660
|
)
|
$
|
2,679
|
$
|
844
|
||||||
Basic and diluted net earnings (loss) attributable to the parent interest per share
|
$
|
(0.11
|
)
|
$
|
(0.08
|
)
|
$
|
0.05
|
$
|
0.02
|
Quarters ended
|
||||||||||||||||
May 31,
2017
|
February 28,
2017
|
November 30,
2016
|
August 31,
2016
|
|||||||||||||
Sales
|
$
|
58,505
|
$
|
60,030
|
$
|
61,785
|
$
|
62,858
|
||||||||
Cost of sales (1)
|
$
|
24,555
|
$
|
22,989
|
$
|
22,813
|
$
|
24,145
|
||||||||
Net earnings (loss) attributable to the parent interest
|
$
|
(4,304
|
)
|
$
|
1,008
|
$
|
3,303
|
$
|
2,252
|
|||||||
Basic and diluted net earnings (loss) attributable to the parent interest per share
|
$
|
(0.08
|
)
|
$
|
0.02
|
$
|
0.06
|
$
|
0.04
|
(1)
|
The cost of sales is exclusive of depreciation and amortization.
|
1. |
Review: I have reviewed the interim financial report and interim MD&A (together, the "interim filings") of EXFO Inc. (the "issuer") for the interim period ended May 31, 2018.
|
2. |
No misrepresentation: Based on my knowledge, having exercised reasonable diligence, the interim filings do not contain any untrue statement of a material fact or omit to state a material fact required to be stated or that is necessary to make a statement not misleading in light of the circumstances under which it was made, with respect to the period covered by the interim filings.
|
3. |
Fair presentation: Based on my knowledge, having exercised reasonable diligence, the interim financial report together with the other financial information included in the interim filings fairly present in all material respects the financial condition, financial performance and cash flows of the issuer, as of the date of and for the periods presented in the interim filings.
|
4. |
Responsibility: The issuer's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (DC&P) and internal control over financial reporting (ICFR), as those terms are defined in Regulation 52-109 respecting Certification of Disclosure in Issuer's Annual and Interim Filings (c. V-1.1, r. 27), for the issuer.
|
5. |
Design: Subject to the limitations, if any, described in paragraphs 5.2 and 5.3, the issuer's other certifying officer and I have, as at the end of the period covered by the interim filings
|
(a) |
designed DC&P, or caused it to be designed under our supervision, to provide reasonable assurance that
|
(i) |
material information relating to the issuer is made known to us by others, particularly during the period in which the interim filings are being prepared; and
|
(ii) |
information required to be disclosed by the issuer in its annual filings, interim filings or other reports filed or submitted by it under securities legislation is recorded, processed, summarized and reported within the time periods specified in securities legislation; and
|
(b) |
designed ICFR, or caused it to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with the issuer's GAAP.
|
5.1 |
Control framework: The control framework the issuer's other certifying officer and I used to design the issuer's ICFR is the Internal Control – Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).
|
5.2 |
N/A
|
5.3 |
Limitation on scope of design: The issuer has disclosed in its interim MD&A
|
(a)
|
the fact that the issuer's other certifying officer and I have limited the scope of our design of DC&P and ICFR to exclude controls, policies and procedures of a business that the issuer acquired not more than 365 days before the last day of the period covered by the interim filing; and
|
(b)
|
summary financial information about the business that the issuer acquired that has been proportionately consolidated or consolidated in the issuer's financials statements.
|
6. |
Reporting changes in ICFR: The issuer has disclosed in its interim MD&A any change in the issuer's ICFR that occurred during the period beginning on March 1, 2018 and ended on May 31, 2018 that has materially affected, or is reasonably likely to materially affect, the issuer's ICFR.
|
1. |
Review: I have reviewed the interim financial report and interim MD&A (together, the "interim filings") of EXFO Inc. (the "issuer") for the interim period ended May 31, 2018.
|
2. |
No misrepresentation: Based on my knowledge, having exercised reasonable diligence, the interim filings do not contain any untrue statement of a material fact or omit to state a material fact required to be stated or that is necessary to make a statement not misleading in light of the circumstances under which it was made, with respect to the period covered by the interim filings.
|
3. |
Fair presentation: Based on my knowledge, having exercised reasonable diligence, the interim financial report together with the other financial information included in the interim filings fairly present in all material respects the financial condition, financial performance and cash flows of the issuer, as of the date of and for the periods presented in the interim filings.
|
4. |
Responsibility: The issuer's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (DC&P) and internal control over financial reporting (ICFR), as those terms are defined in Regulation 52-109 respecting Certification of Disclosure in Issuer's Annual and Interim Filings (c. V-1.1, r. 27), for the issuer.
|
5. |
Design: Subject to the limitations, if any, described in paragraphs 5.2 and 5.3, the issuer's other certifying officer and I have, as at the end of the period covered by the interim filings
|
(a) |
designed DC&P, or caused it to be designed under our supervision, to provide reasonable assurance that
|
(i) |
material information relating to the issuer is made known to us by others, particularly during the period in which the interim filings are being prepared; and
|
(ii) |
information required to be disclosed by the issuer in its annual filings, interim filings or other reports filed or submitted by it under securities legislation is recorded, processed, summarized and reported within the time periods specified in securities legislation; and
|
(b) |
designed ICFR, or caused it to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with the issuer's GAAP.
|
5.1 |
Control framework: The control framework the issuer's other certifying officer and I used to design the issuer's ICFR is the Internal Control – Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).
|
5.2 |
N/A
|
5.3 |
Limitation on scope of design: The issuer has disclosed in its interim MD&A
|
(a)
|
the fact that the issuer's other certifying officer and I have limited the scope of our design of DC&P and ICFR to exclude controls, policies and procedures of a business that the issuer acquired not more than 365 days before the last day of the period covered by the interim filing; and
|
(b)
|
summary financial information about the business that the issuer acquired that has been proportionately consolidated or consolidated in the issuer's financials statements.
|
6. |
Reporting changes in ICFR: The issuer has disclosed in its interim MD&A any change in the issuer's ICFR that occurred during the period beginning on March 1, 2018 and ended on May 31, 2018 that has materially affected, or is reasonably likely to materially affect, the issuer's ICFR.
|